Abeona Therapeutics (ABEO) EBITDA Margin (2011 - 2026)

Abeona Therapeutics' EBITDA Margin history runs 13 years deep, the most recent figure standing at 264.14% for Q1 2026.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 264.14% in Q1 2026; TTM through Mar 2026 was 637.92%, a N/A change from a year earlier, with the FY2025 full-year figure at 1536.91%, changed N/A from the prior year.
• EBITDA Margin advanced to 264.14% in Q1 2026 per ABEO's latest filing, from 422.71% in the prior quarter.
• Across five years, EBITDA Margin topped out at 264.14% in Q1 2026 and bottomed at 19023.53% in Q4 2022.
• The 4-year median for EBITDA Margin is 800.8% (2022), against an average of 4637.41%.
• Biggest YoY gain for EBITDA Margin was 49926 bps in 2023; the steepest drop was 49926 bps in 2023.
• Year by year, EBITDA Margin stood at 19023.53% in 2022, then soared by 98 bps to 301.54% in 2023, then sank by 40 bps to 422.71% in 2025, then jumped by 38 bps to 264.14% in 2026.
• Per Business Quant, the three latest ABEO EBITDA Margin figures stand at 264.14% (Q1 2026), 422.71% (Q4 2025), and 5698.0% (Q2 2025).